FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Para fins de pesquisa apenas. Leia o disclaimer completo →

Biblioteca de Peptídeos

Cardiogen

Ala-Glu-Asp-Arg / AEDR peptide

Longevity & Anti-Aging

Cardiogen is a synthetic tetrapeptide (Ala-Glu-Asp-Arg) developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, designed as a bioregulator peptide specific to cardiac tissue. It is theorized to normalize gene expression in cardiomyocytes by penetrating cell nuclei and interacting with DNA regulatory sequences. Research applications focus on cardiac tissue repair, prevention of age-related myocardial deterioration, and post-ischemic cardioprotection.

Mecanismo de Ação

Synthetic tetrapeptide bioregulator that targets cardiac tissue. Promotes cardiomyocyte differentiation, enhances cardiac stem cell activity, and may improve myocardial function by modulating gene expression in heart tissue. Part of the Khavinson bioregulator class.

Protocolos de Pesquisa

Para fins de pesquisa apenas. Não é conselhos médicos.

Research protocols (Khavinson method) use 10-20mg orally or sublingually daily for 10-30 day cycles. Sublingual preferred. Cycles repeated every 3-6 months.

Notas de Pesquisa

Clinical Research Status

Cardiogen has been investigated in clinical studies conducted primarily in Russia, with reports of improved cardiac function markers in elderly patients with age-related cardiovascular deterioration. Studies have examined its use both as a standalone intervention and in combination with other bioregulator peptides as part of comprehensive anti-aging protocols. It is available as a supplement in Russia but has not been evaluated by Western regulatory agencies or subjected to large-scale randomized controlled trials meeting international standards.

Key Published Findings

Research demonstrates that Cardiogen can stimulate proliferation and differentiation of cardiac stem cells in vitro, potentially contributing to myocardial regeneration. Animal studies show reduced infarct size and improved left ventricular function when administered following experimental myocardial ischemia. Gene expression analysis indicates upregulation of cardioprotective factors including heat shock proteins and anti-apoptotic genes in cardiomyocyte cultures exposed to Cardiogen.

Safety Profile

Available literature reports no adverse effects from Cardiogen administration at recommended doses, consistent with the general safety profile of ultrashort bioregulator peptides. Its constituent amino acids (alanine, glutamic acid, aspartic acid, arginine) are all naturally occurring and rapidly metabolized through normal physiological pathways. No contraindications have been formally established, though patients with active cardiac conditions should not use investigational peptides as substitutes for established medical treatments.

Comparison to Related Compounds

Cardiogen is tissue-specific to cardiac muscle, while the related Khavinson peptide Vessels (Lys-Glu-Asp-Trp) targets vascular endothelium, and Thymalin addresses immune function. Unlike BPC-157, which provides general tissue healing through angiogenesis and growth factor modulation, Cardiogen is theorized to work through direct gene regulatory mechanisms specific to cardiomyocytes. Compared to pharmaceutical cardioprotective agents like trimetazidine, Cardiogen represents a fundamentally different approach through peptide bioregulation rather than metabolic modulation.

Community Observations

Users in longevity-focused communities often incorporate Cardiogen as part of broader Khavinson peptide stacks targeting multiple organ systems simultaneously. Reported benefits are generally subtle and difficult to verify without echocardiographic or biomarker monitoring, making subjective assessment challenging. The peptide is typically used in 10-30 day cycles several times per year, following protocols established in Russian gerontological practice.

Meio-Vivo

~15-30 minutes

Reconstituição

N/A (typically oral/sublingual capsule)

Armazenamento

Liofilizado

Room temperature. Protect from moisture.

Reconstituído

N/A (oral form)

Situação Legal nos EUA

Research chemical (not FDA-approved)

Também Conhecido Como

Ala-Glu-Asp-ArgAEDR peptide

Perguntas frequentes

O que é Cardiogen?

Cardiogen is a synthetic tetrapeptide (Ala-Glu-Asp-Arg) developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, designed as a bioregulator peptide specific to cardiac tissue. It is theorized to normalize gene expression in cardiomyocytes by penetrating cell nuclei and interacting with DNA regulatory sequences. Research applications focus on cardiac tissue repair, prevention of age-related myocardial deterioration, and post-ischemic cardioprotection.

Como Cardiogen funciona?

Synthetic tetrapeptide bioregulator that targets cardiac tissue. Promotes cardiomyocyte differentiation, enhances cardiac stem cell activity, and may improve myocardial function by modulating gene expression in heart tissue. Part of the Khavinson bioregulator class.

Qual é o status regulatório de Cardiogen nos EUA?

Research chemical (not FDA-approved)

Qual é a meia-vida de Cardiogen?

~15-30 minutes

Por quais outros nomes Cardiogen é conhecido?

Ala-Glu-Asp-Arg, AEDR peptide

Peptide Contacts fornece resumos baseados em pesquisas apenas para fins informativos. Não hospedamos, distribuímos ou endossamos documentação de fornecedores. Todas as certificações de análise completa, certificados GMP e comunicações de fornecedores devem ser solicitadas e verificadas diretamente pelo comprador. Nada nesta plataforma constitui conselhos legais, médicos ou profissionais. Os usuários são unicamente responsáveis por verificar as credenciais dos fornecedores e garantir a conformidade com todas as leis locais, estaduais e federais aplicáveis antes de adquirir qualquer química de pesquisa. O uso desta plataforma constitui aceitação plena da responsabilidade pessoal.

Leia a declaração completa